平安证券股份有限公司 关于四川梓橦宫药业股份有限公司 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是，保荐代表人根据相关规定，及时审阅 | | | 公司发布的三会公告、定期报告及其他事 | | | 项公告等在内的有关信息披露文件 | | （2）未及时审阅公司信息披露文件的次数 无 | | | 2.督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包 括但不限于防止关联方占用公司资源的制 | 是，已持续督导公司建立健全相关规章制 | | 度、募集资金管理制度、内控制度、内部 度 | | | 审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 是 | | | 3.募集资金使用监督情况 | | | （1）查询公司募集资金专户次数 2 | 次。保荐机构每半年度均通过查阅银行 | | | 对账单等方式对募集资金专户进行查询。 | | | 并通过核对明细账、原始凭证及募集资金 | | | 项目投资所涉及合同、查勘募投项目现场 | | | 的方式核查募集资金存放和使用情 ...

Group 1: Industry Outlook and Company Performance - The health industry is considered a long-term growth sector, supported by policies, rising health awareness, and an aging population [6] - In 2024, the company's revenue was CNY 415.67 million, with a net profit of CNY 85.64 million, and earnings per share of CNY 0.59 [6] - The pharmaceutical manufacturing industry faced a 3.3% decline in profits, with a 2.0% increase in operating costs and a 1.1% decrease in total profits [6] Group 2: Financial Challenges and Strategies - The net profit decreased by CNY 13.77 million due to increased R&D expenses (CNY 3.92 million), higher employee salaries (CNY 2.37 million), and reduced investment income (CNY 6.59 million) [6] - Key strategies for 2025 include focusing on chronic disease medications, optimizing product structure, and enhancing R&D collaboration with universities and research institutions [7] Group 3: Market and Product Development - The company aims to enhance its market presence by launching new products and improving brand recognition [7] - The sales revenue for the new product, Su Lin Puri Ba Lin oral solution, reached CNY 6.98 million in 2024, a 50.3% increase year-on-year [8] - The company’s largest single product, Sodium Cytidine, targets the elderly demographic, addressing conditions like cerebrovascular accidents and dementia [9] Group 4: R&D and Innovation - The company has initiated over 10 new drug R&D projects and plans to increase investment in innovative drug development [6] - The Ma Jia Zi capsule, a new drug targeting gastrointestinal tumors, has entered Phase Ia clinical trials [10] - The company is committed to integrating AI and big data into its R&D and production processes to enhance efficiency [9] Group 5: Market Strategy and Shareholder Returns - The company plans to establish a stable and transparent profit distribution mechanism to enhance shareholder returns [6] - It will continue to monitor market trends and may consider stock buybacks in the future [6] - The company is focused on maintaining a balance between market value and intrinsic value through strategic management [6]

Core Insights - The company conducted a video live-streaming event to interact with investors, presenting a comprehensive overview of its business performance and strategic planning, enhancing investors' understanding of the annual report's key content [2] Financial Performance - In 2024, the company achieved an operating income of 415.67 million yuan and a net profit of 85.64 million yuan, with a basic earnings per share of 0.59 yuan [4] Product Development - The company currently has an influenza treatment drug, Oseltamivir Phosphate Capsules, and cold medications including Amantadine Hydrochloride Capsules and Paracetamol Tablets [4] - The company is advancing its research pipeline with a new drug, Maja Zhi Capsules, targeting gastrointestinal tumors, which has entered Phase Ia clinical trials [4] - A generic drug, Fumarate Vornorate Tablets, has been submitted for drug registration approval [4] - New projects initiated in 2024 include Tartrate Sinibiri Tablets, Ibuprofen Sustained-Release Capsules, Dydrogesterone Tablets, and Lidocaine Hydrochloride Sterile Gel [4] Strategic Focus - The company emphasizes "innovation-driven" development, aiming to accelerate research and development, marketing, and management innovations to lay a solid foundation for the successful launch of its 14th Five-Year Plan [4]

Core Viewpoint - Sichuan Zimuongong Pharmaceutical Co., Ltd. is focusing on innovation and market expansion while enhancing production capacity and management efficiency to drive future growth [2][3]. Group 1: Company Overview - Zimuongong has a history of 245 years and specializes in drug research, production, and marketing, holding 26 invention patents and 99 drug production approvals across various forms [2]. - The company is primarily focused on the development of drugs for the nervous system and digestive system, with future emphasis on endocrine and analgesic drugs [2]. Group 2: Financial Performance - In 2024, Zimuongong achieved a revenue of 416 million yuan, a year-on-year increase of 1.87%, and a net profit attributable to shareholders of 85.64 million yuan [3]. - The company plans to distribute a cash dividend of 2 yuan per 10 shares, totaling approximately 29.31 million yuan, with the total cash dividends over the last three years amounting to about 144 million yuan, representing 149.21% of the average annual net profit [4]. Group 3: Research and Development - Zimuongong increased its R&D investment by 81.18% compared to the same period in 2023, focusing on both innovative and generic drugs [3]. - The company is advancing its innovative drug pipeline, including the initiation of clinical trials for the Ma Jia Zi capsule and the successful launch of the Phosphate Oseltamivir capsule [3]. Group 4: Future Strategy - The company aims to adhere to its core business in pharmaceutical manufacturing while driving growth through innovation and marketing, focusing on both internal growth and external expansion [4].

证券代码：832566 证券简称：梓橦宫 公告编号：2025-038 四川梓橦宫药业股份有限公司 关于使用自有闲置资金委托理财的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 授权委托理财情况 （一）购买理财产品的审议情况 四川梓橦宫药业股份有限公司（以下简称"公司"）于 2024 年 9 月 26 日 召开第四届董事会第八次会议及 2024 年 10 月 18 日召开 2024 年第三次临时股 东会，审议通过了《关于使用自有闲置资金购买理财产品的议案》。为提高公 司资金的使用效率，增加投资收益，在不影响公司主营业务的正常发展，并确 保公司正常经营需求的前提下，公司拟使用不超过人民币 29,000.00 万元（含） 自有闲置资金购买低风险类短期理财产品，获取额外的资金收益，自股东会审 议通过之日起 12 个月内有效。具体内容详见公司 2024 年 9 月 26 日在北京证 券交易所披露平台（http://www.bse.cn）披露的《关于使用自有闲置资金购买 理财产品的公告》（公告编号： ...

| | 专利类型 | 专利名称 | | 专利号 | | | 授权公告日 | | | | 专利权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 外观设计 | 药盒（东方胃 药胶囊 1） | ZL | 2024 | 3 0594734.1 | 2025 | 年 05 | 月 | 13 | 日 | 四川梓橦宫药业 股份有限公司 | | | 外观设计 | 药盒（东方胃 药胶囊 2） | ZL | 2024 | 3 0594733.7 | 2025 | 年 05 | 月 | 13 | 日 | 四川梓橦宫药业 股份有限公司 | | 序号 1 2 | | | | | | | | | | | | 证券代码：832566 证券简称：梓橦宫 公告编号：2025-039 四川梓橦宫药业股份有限公司 关于取得 2 项外观设计专利证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 基本情况 近日，四川 ...

保荐工作总结报告书 根据中国证券监督管理委员会《关于核准四川梓橦宫药业股份有限公司向不 特定合格投资者公开发行股票的批复》（证监许可〔2021〕2369 号），四川梓橦 宫药业股份有限公司（以下简称梓橦宫或公司）向不特定合格投资者公开发行人 民币普通股股票 19,000,000 股（含行使超额配售选择权），2021 年 8 月 13 日起 在全国中小企业股份转让系统精选层挂牌，并于 2021 年 11 月平移至北京证券交 易所。平安证券股份有限公司（以下简称平安证券或保荐机构）担任梓橦宫向不 特定合格投资者公开发行股票（以下简称本次发行）的保荐机构，持续督导期限 截至 2024 年 12 月 31 日。 一、保荐机构及保荐代表人承诺 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导 性陈述或重大遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担法 律责任。 2、保荐机构及本人自愿接受中国证监会和北京证券交易所对保荐总结报告 书相关事项进行的任何质询和调查。 3、保荐机构及本人自愿接受中国证监会按照《证券发行上市保荐业务管理 办法》的有关规定采取的监管措施。 二、保荐机构基本情况 | 保 ...

Group 1 - The company demonstrated resilience and steady development despite the overall downturn in the industry, achieving an operating income of 416 million yuan and a net profit of 85.64 million yuan, with a gross margin of 78.80% [1] - The business layout is centered around neuro and digestive system drugs, with strong sales from products like cytidine diphosphate sodium tablets, which serve as a stabilizing force for the company's performance [1] - The company significantly increased its R&D investment, with R&D expenses accounting for 9.55% of revenue and capitalized R&D expenditures rising to 73.66%, indicating a robust conversion of research outcomes [1] Group 2 - Continuous innovation in R&D is providing strong momentum for the company's sustainable development, with expectations for future performance to reach new heights [2] - The company achieved new milestones in market expansion, with products like pregabalin oral solution selected in the 10th batch of national drug centralized procurement, and rapid sales growth for new and existing products [2] - The company plans to maintain its innovation-driven development strategy, enhance core competitiveness, and strategically invest to expand business areas and market space, contributing to the healthcare sector [2]

证券代码：832566 证券简称：梓橦宫 公告编号：2025-015 四川梓橦宫药业股份有限公司 第四届监事会第十一次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 5.会议主持人：监事会主席蒋晓风 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开、议案审议程序符合《公司法》等有关法律、行政法 规、部门规章、规范性文件和《公司章程》《监事会议事规则》等有关规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《2024 年度监事会工作报告》 1.议案内容： 根据相关法律法规和《公司章程》等要求，公司监事会主席向监事会汇报了 2024 年度监事会工作情况。 1.会议召开时间：2025 年 4 月 25 日 2.会议召开地点：公司会议室 3.会议召开方式：现场召开 4.发出监事会会议通知的时间和方式：2025 年 4 月 14 日以书面方式发出 2.议案表决结果：同意 3 票；反 ...